|
|
|
|
|
|
|
In Vitro Dissolution Methodologies For Amorphous Solid Dispersions
|
|
|
With the availability of so many types of in vitro dissolution tests, how do you determine which one will be most effective in predicting in vivo performance of your BCS II or IV drug product? Choose your methodology based on the key challenge to accurately assess and improve oral bioavailability.
|
|
|
|
|
|
|
The prevalence of active compounds with low aqueous solubility exceeds 70% in drug pipelines, preventing the development of many compounds as effective medicines. A novel formulation platform makes it possible to meet the requirements for a successful high-loading spray-dried ASD dosage form, reducing tablet mass by nearly half to meet patient needs.
|
|
|
|
|
A growing number of drugs in the development pipeline are poorly soluble in gastrointestinal fluids, and can severely limit oral bioavailability. This talk describes how an amorphous solid dispersion (ASD) of acalabrutinib was designed using in vitro studies and in silico modeling. Watch now to understand how ASD formulations can enhance bioavailability.
|
|
|
|
|
|
|
|
Extrusion-Based ASD Scale-Up: Ensuring Performance Through Process Understanding
|
Boost your drug development success with Lonza’s upcoming webinar on amorphous solid dispersions (ASDs). Learn how hot melt extrusion (HME) can enhance bioavailability, cut costs, and scale efficiently — backed by real-world lab and pilot trials. Compare HME and spray drying while gaining exclusive insights into Lonza’s advanced capabilities and proven expertise in ASD manufacturing. Don’t miss it! Click here to learn more.
|
|
|
